** Trajan Group TRJ.AX jumps 8.6% to A$0.880, highest since May 27
** Stock set for its best day since March 12, if trend holds
** Life sciences products developer expects FY25 revenue to exceed upper-end of guidance at A$166.5 mln ($107.68 mln)
** Sees FY25 group EBITDA at A$15.5 mln, 8.8% below lower-end of guidance
** YTD, TRJ falls 22.1%
($1 = A$1.5463)
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.SinghChundawat@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。